May 5, 2020 / 12:32 PM / 20 days ago

BRIEF-FDA Clears Lipocine's LPCN 1148 IND Application For Phase 2 Cirrhosis Trial

May 5 (Reuters) - Lipocine Inc:

* FDA CLEARS LPCN 1148 IND APPLICATION FOR PHASE 2 CIRRHOSIS TRIAL

* LIPOCINE INC - CONTINGENT UPON AVAILABLE FUNDING, PROJECTS STUDY INITIATION IN Q4 OF 2020 OR Q1 OF 2021 FOR PHASE 2 CIRRHOSIS TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below